Investor Presentation January 2026 Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's expected revenue for the fourth quarter and full year ended December 31, 2025; Cytek's market position and long-term market expansion opportunities; Cytek's business, product and operational goals and strategies; and Cytek's opp ...

Financial Performance & Outlook - Cytek's 2024 revenue reached $200.5 million, a 4% year-over-year increase[14] - Adjusted EBITDA for 2024 was $22.4 million, representing a 77% year-over-year growth[14] - The company anticipates revenue between $204 million and $212 million for 2025[11] - Cytek has authorized a $50 million share repurchase program[11] Market Position & Growth - Cytek has placed 3,034 units of its instruments[8] - The company has a broad customer base of approximately 2,000 customers across 70+ countries[8] - The initial total addressable market (TAM) for cell analysis in 2025 is estimated at $7.5 billion[20] - The adjacent TAM is estimated at $8.5 billion[20] Product & Technology - Cytek's FSP (Full Spectrum Profiling) technology underpins its core instruments[28] - Amnis ImageStream revenue experienced 14% growth in 2024[32] - The company's cloud-based operating system has over 16,000 users, with a user base growth of over 160% in 2024[42]